Geraghty, 2019 - Google Patents
The Role of Purinergic Signalling in Inflammatory DisordersGeraghty, 2019
- Document ID
- 13111668777678945758
- Author
- Geraghty N
- Publication year
External Links
- 230000011664 signaling 0 title abstract description 63
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by the preceding groups
- G01N33/48—Investigating or analysing materials by specific methods not covered by the preceding groups biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
- G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
- G01N33/5047—Cells of the immune system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/21—Interferons [IFN]
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Thiault et al. | Peripheral regulatory T lymphocytes recirculating to the thymus suppress the development of their precursors | |
Hänsel et al. | Human slan (6-sulfo LacNAc) dendritic cells are inflammatory dermal dendritic cells in psoriasis and drive strong TH17/TH1 T-cell responses | |
Kulkarni et al. | CCR6 signaling inhibits suppressor function of induced-Treg during gut inflammation | |
Geraghty et al. | The P2X7 receptor antagonist Brilliant Blue G reduces serum human interferon-γ in a humanized mouse model of graft-versus-host disease | |
Snyder et al. | PRMT5 regulates T cell interferon response and is a target for acute graft-versus-host disease | |
AU2016270996A1 (en) | Methods to induce conversion of regulatory T cells into effector T cells for cancer immunotherapy | |
KR20210061341A (en) | Novel LILRB4 antibodies and uses thereof | |
Liang et al. | Roles of the Adenosine Receptor and CD73 in the Regulatory Effect of γδ T Cells | |
Manni et al. | Pharmacologic induction of endotoxin tolerance in dendritic cells by L-kynurenine | |
EP3024482A2 (en) | Methods for diagnosing and treating immune disease | |
Said et al. | Bacterially activated B-cells drive T cell differentiation towards Tr1 through PD-1/PD-L1 expression | |
Bachus et al. | IL-6 prevents Th2 cell polarization by promoting SOCS3-dependent suppression of IL-2 signaling | |
Bryant et al. | Expression and function of NOD-like receptors by human term gestation-associated tissues | |
Geraghty et al. | Increased splenic human CD4+: CD8+ T cell ratios, serum human interferon-γ and intestinal human interleukin-17 are associated with clinical graft-versus-host disease in humanized mice | |
JP6721145B2 (en) | Memory invariant NKT cell marker | |
Geraghty | The Role of Purinergic Signalling in Inflammatory Disorders | |
Burleson et al. | The immune basis of allergic lung disease | |
US10633704B2 (en) | Diagnostic and immunotherapy compositions and methods for disease states mediated by inhibitor-resistant CD8 T-cells | |
US20220213198A1 (en) | Method of treatment | |
Lory | Adenine nucleotide-modulated CD8+ T cell differentiation and effector functions | |
Han | E3 Ubiquitin Ligase Cbl-b deficient T cells resist Treg cell-mediated suppression and enhance anti-tumor immunity | |
EP4052727A1 (en) | Immune response suppressor | |
Adhikary | Therapeutic Strategies to Prevent Graft-Versus-Host Disease | |
Muckenhuber et al. | IL-6 inhibition prevents costimulation blockade-resistant allograft rejection in T cell-depleted recipients by promoting intragraft immune regulation in mice | |
Georgiev | Chemokine orchestration of leukocyte-skin interactions |